Bruker Corporation Completes Acquisition of Chemspeed Technologies AG, Enhancing Automation and Digitalization Capabilities

08 March 2024 | Friday | News

Strategic Move Further Advances Bruker’s Project Accelerate 2.0 Initiative with Focus on Automated R&D and QC Solutions

Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful closing of its acquisition of Chemspeed Technologies AG, a leading Swiss provider of automated laboratory R&D and QC workflow solutions. This acquisition, first announced in January 2024, marks another significant milestone in Bruker’s expansion in vendor-agnostic scientific software, R&D and QC digitalization, and laboratory automation – altogether an important initiative within Bruker’s strategic Project Accelerate 2.0 portfolio transformation.

Mr. Bernd Gleixner, President of the new Automation Division at Bruker BioSpin, and now Managing Director of Chemspeed, commented: “We are excited about the opportunities this acquisition brings, and we warmly welcome the excellent Chemspeed team to Bruker. Going forward, Chemspeed will continue to operate as a vendor-agnostic, standalone business within Bruker, maintaining its commitment to industry-leading automated laboratory solutions and customer service.”

As part of Bruker, Chemspeed is expected to be near break-even for the remaining three quarters of 2024, with approximately $10 million of revenue per quarter, as it transitions to US GAAP reporting and aligns with Bruker’s revenue recognition policies. By 2025, we anticipate Chemspeed to be 2-3 cents accretive to Bruker’s non-GAAP EPS. Going forward, we expect high-single digit to low double-digit organic revenue growth and steady, significant margin expansion. The Chemspeed acquisition is a testament to Bruker’s commitment to strategic expansion and innovation in the fields of automated R&D and QC laboratory solutions, lab digitalization and scientific software.

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close